1 Unpopular Stock That Deserves a Second Chance and 2 Facing Challenges
By:
StockStory
October 28, 2025 at 00:31 AM EDT
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory. Accurately determining a company’s long-term prospects isn’t easy, especially when sentiment is weak. That’s where StockStory comes in - to help you find attractive investment candidates backed by unbiased research. That said, here is one stock where you should be greedy instead of fearful and two where the skepticism is well-placed. Two Stocks to Sell:Best Buy (BBY)Consensus Price Target: $80.71 (-1.8% implied return) With humble beginnings as a stereo equipment seller, Best Buy (NYSE: BBY) now sells a broad selection of consumer electronics, appliances, and home office products. Why Does BBY Give Us Pause?
Best Buy’s stock price of $82.18 implies a valuation ratio of 12.8x forward P/E. Check out our free in-depth research report to learn more about why BBY doesn’t pass our bar. Proto Labs (PRLB)Consensus Price Target: $50 (-8% implied return) Pioneering the concept of online quoting and manufacturing for custom prototypes and low-volume production parts, Proto Labs (NYSE: PRLB) offers injection molding, 3D printing, and sheet metal fabrication for manufacturers in various industries. Why Do We Pass on PRLB?
At $54.35 per share, Proto Labs trades at 35.5x forward P/E. If you’re considering PRLB for your portfolio, see our FREE research report to learn more. One Stock to Watch:AbbVie (ABBV)Consensus Price Target: $237.48 (4.4% implied return) Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE: ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions. Why Do We Like ABBV?
AbbVie is trading at $227.50 per share, or 19.4x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free for active Edge members. Stocks We Like Even MoreTrump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines. Take advantage of the rebound by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. More NewsView More
Five Below and Dollar Tree Earnings Signal a Shopper Shift ↗
Today 7:15 EST
Via MarketBeat
Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead? ↗
December 06, 2025
Via MarketBeat
Tickers
ULTA
Gates Foundation Sells MSFT Stock—Should Investors Be Worried? ↗
December 06, 2025
Via MarketBeat
Tickers
MSFT
MarketBeat Week in Review – 12/1 - 12/5 ↗
December 06, 2025
Recent QuotesView More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
|
